News

Arctic Vision Announced Positive Topline Results of Phase III Clinical Trial of Suprachoroidal Space Injection Therapy ARVN001 for Uveitic Macular Edema Patients in China

2024-7-26

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs

2024-5-07

SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease

2024-1-05

Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb

2023-9-06

与诺华“联姻”后，Chinook又携两项核心资产“炸场”ERA年会

2023-6-21

神领锐医药宣布与台湾晶实公司签署独家经销协议

2023-4-20

合凯维生命科学首次亮相，完成近千万美元的种子轮融资，进军全球女性健康市场

2023-3-08

2022 ASN肾脏周披露最新数据 | BION-1301治疗显著降低IgA肾病患者尿蛋白水平

2022-11-16

Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics

2022-11-07

Arctic Vision Announces First Patient Enrolled in Phase III Clinical Trialof ARVN002 for Progressive Myopia This marks yet another successful expansion of Arctic Vison's MAP™ technology in the field of ophthalmic therapeutics

2022-9-28

Arctic Vision Announces First-Ever Application of Triamcinolone Acetonide Injectable Suspension for Suprachoroidal Use for the Treatment of UME in Boao

2022-9-26

OncXerna Therapeutics Doses First Patient in Phase 2 Trial Evaluating Navicixizumab Alone or in Combination with Chemotherapy in Patients with Select Advanced Solid Tumors

2022-9-12

Ablaze Pharma Aligned The Strategic Agreement With Wenjiang District Government of Chengdu to Build-up the Innovative R&D and Manufacturing Center for Targeted Radiopharmaceutical Therapies

2022-8-05

Novaremed enters into an exclusive option and license agreement with NeuroFront for the non-opioid neuropathic pain treatment, NRD.E1, for Greater China and Singapore

2022-7-21

Arctic Vision Announces First Patient Enrolled in Phase III Clinical Trial of ARVN003 for Presbyopia

2022-7-04

Arctic Vision Announces First Patient Dosed in Phase 1 Clinical Trial of ARVN001 for the Treatment of Diabetic Macular Edema (DME) in China

2022-3-03

Plexium Announces $102m Financing to Advance Pipeline of Targeted Protein Degradation Therapies and Technology Platform

2022-2-23

OncXerna is selected as Global Top 5 Precision Medicine Startups

2022-2-17

Arctic Vision Enters Strategic Partnership with MediTrust Health to Improve Accessibility and Affordability of Innovative Ophthalmic Drugs in China

2022-1-26

Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients

2022-1-10

Arctic Vision Wins Leading-Edge Enterprise of the Year Award at the 36Kr WISE 2021 New Economy Summit

2021-12-14

Pivotal bioVenture Partners China Announces Formation of SanReno Therapeutics

2021-12-03

Ablaze Pharmaceuticals Launches with $75m Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market

2021-11-29

Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

2021-11-23

Arctic Vision Enters Strategic Collaboration with Eye Hospital, WMU

2021-11-12

Arctic Vision Enters Strategic Partnership with SPH Health Commerce to Boost Development and Delivery of Innovative Ophthalmology Therapies in China

2021-11-05

Arctic Vision announced residency at JLABS @ Shanghai to further the Development of Innovative Ophthalmic Therapy Discovery Platform

2021-11-03

Arctic Vision’s Collaboration Partner, Clearside Biomedical Inc., Has Obtained U.S. FDA Approval of XIPERE™ (ARVN001) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis

2021-10-26

Arctic Vision Announces Addition of Novel Mydriatic Drug MydCombi™ (ARVN004) to Eyenovia Commercialization Deal

2021-9-17

Arctic Vision Announces 2nd Expansion of License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include Australia and New Zealand

2021-9-10

Arctic Vision Obtains China IND Clearance for Phase III Study of ARVN003, the First in China for Presbyopia Treatment

2021-9-03

Arctic Vision Announces Expansion of License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include ASEAN Countries and India

2021-8-15

QIAGEN and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements

2021-8-09

Engrail Therapeutics Extends Series A Financing to $64 Million

2021-8-03

Arctic Vision Received China IND Clearance for Phase III Study of ARVN002 to Reduce Paediatric Myopia Progression

2021-8-02

NeuroFront Announces Exclusive Licensing Agreement for Development and Commercialization of Neurolief’s Relivion® in Greater China and South Korea

2021-7-09

Exscientia announces investment of up to $525M

2021-4-26

Evommune完成1250万美元种子轮融资

2020-11-20

Oncologie（鼎航医药）公布最新临床研究数据

2020-9-21

Arctic Vision Announces US$32MN in Series A

2020-7-14

Oncologie Launches with 16.5M USD Seed Funding Led by Pivotal bioVenture Partners China

2018-6-07

Pivotal bioVenture Partners China Closes Inaugural $150 Million Early Stage VC Fund

2018-5-24